Skip to main content


Scientific Name(s): 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one, 3, 3′, 4′, 5, 7-pentahydroxy-2-phenylchromen-4-one, 3,3′,4′,5,7-pentahydroxyflavone
Common Name(s): Pentahydroxyflavone, Quercetin, Quercetine, Vitamin P

Medically reviewed by Last updated on Dec 19, 2022.

Clinical Overview


Interest in quercetin as an antioxidant is ongoing. Chemoprotective and antihypertensive effects show promise, but clinical studies are limited. Preliminary data indicate potential benefit for improving adaptive and social functioning in children with autism.


Although specific evidence to support dosing recommendations is limited, most clinical studies use quercetin 500 to 1,000 mg per day in divided doses.


Contraindications have not been identified. Avoid coadministration with the cardiac glycoside digoxin.


Generally recognized as safe (GRAS) when consumed as food. Avoid dosages above those found in foods because information regarding safety and efficacy in pregnancy and lactation is lacking for such doses. Fetal growth retardation was observed in a study in rats exposed to quercetin by oral gavage.


See Drug Interactions section.

Adverse Reactions

No clinically important adverse effects were reported in clinical studies.


Oral supplemental doses of up to 1,000 mg per day for as long as 12 weeks showed no evidence of toxicity. However, data on long-term safety at high doses are lacking, and concerns regarding carcinogenicity remain unresolved. Nephrotoxicity has been reported with high doses of intravenous (IV) quercetin.


The flavonol quercetin is found as glycosides in many vegetables and fruits, as well as in seeds, nuts, flowers, bark, and leaves. Rich sources of quercetin include apples, asparagus, berries, Brassica vegetables (eg, broccoli), capers, grapes, onions, shallots, tea, and tomatoes. Quercetin is also found in large amounts in ginkgo, St. John’s wort, and elder. The outermost layers of onions and dried, not fresh, shallots are rich in quercetin.1, 2, 3, 4, 5 See also Onion monograph.


Initially, quercetin was considered to be a vitamin and given the name "vitamin P." It was identified in the 1930s, but was slow to gain recognition because it did not seem to be an essential micronutrient. As epidemiological studies in the 1990s pointed to the benefits of flavonoids in cardiovascular health, more researchers started investigating quercetin in depth.6


Quercetin (3, 3′, 4′, 5, 7-pentahydroxy-2-phenylchromen-4-one) is a flavonol, sharing the common hydroxylated 3-ringed structure with attached hydroxyl groups of other flavonoids.2 Quercetin is bright yellow and soluble in alcohol and lipids, but poorly soluble in hot water and insoluble in water. The aglycone form is more lipophilic than quercetin glycosides such as rutinoside from tea, and is absorbed more readily than glycoside forms, which must be hydrolyzed to release quercetin. Analytical techniques for the identification of quercetin have been described.1, 5, 7, 8, 9

Uses and Pharmacology

Anti-inflammatory activity

Clinical data

Equivocal data have been published on the anti-inflammatory effects of quercetin(13, 34, 35, 53) Reduced markers of inflammation with quercetin supplementation have been demonstrated in sarcoidosis patients and those with prehypertension.(13, 53) However, no effect on immune measures or inflammation was found in healthy community-dwelling, adult women taking supplemental quercetin 1,000 mg per day over 12 weeks.(34) The effect of quercetin on inflammatory markers was assessed in a double-blind, randomized, placebo-controlled study conducted in 88 adults (98% males) 35 to 65 years of age who had experienced their first myocardial infarction within the past 6 to 8 weeks. Quercetin 500 mg/day or placebo was administered for 8 weeks. Data demonstrated no significant difference between groups in tumor necrosis factor-alpha, hs-C-reactive protein (CRP), or interleukin (IL)-6. Likewise, no differences were noted between groups in overall quality of life, anthropometric measures, physical activity, or blood pressure. No adverse events were reported in the quercetin group.(56)

Antimicrobial effects

Clinical data

A reduction in sick days for respiratory illness was found in middle-aged and elderly subgroups.(35) Antimicrobial effects against HIV and Helicobacter pylori have also been described.(1)

Based on data from 4,521 healthy participants enrolled in 20 randomized controlled trials (including 3 studies with quercetin), meta-analyses demonstrated that flavonoid-containing supplements were safe and effective in preventing acute respiratory tract infections (ARTIs) compared to controls with a relative risk (RR) of 0.81 (95% confidence interval [CI], 0.74 to 0.89; P<0.001) and low heterogeneity. A reduction in mean ARTI sick days was also observed with the supplements; however, heterogeneity was significant (weighted mean difference [WMD], −0.56; 95% CI, −1.04 to −0.08; P=0.021). In subgroup analysis, significance in mean ARTI sick days was retained with flavonoid mixtures (ie, aged garlic extract, cranberry, elderberry, green tea) but not with use of single flavonoids (ie, quercetin, catechin). Pooled results from 16 of the trials indicated that adverse reactions were not increased in the flavonoid supplement groups compared to controls.(95)

Antioxidant activity

Animal data

Quercetin exhibits potent antioxidant activity in experimental models and in animal studies.(1, 7, 10, 11, 12)

Clinical data

Patients with sarcoidosis showed increased plasma antioxidant capacity and reduced markers of oxidative stress and inflammation with quercetin supplementation.(7, 13) However, in a clinical study of quercetin's effect on hypertension, none was found on markers of oxidative stress,(14) and no antioxidant effects were observed in healthy volunteers despite increased plasma quercetin levels.(7) In a double-blind, randomized, placebo-controlled study (N=88; 98% males) in adults who had experienced their first myocardial infarction within the past 6 to 8 weeks, quercetin 500 mg/day for 8 weeks demonstrated an increase in total antioxidant capacity compared to placebo.(56)


Data from a small, prospective, open-label trial (n = 40; 87.5% boys) in children with autism spectrum disorder showed significant improvement in adaptive functioning and overall behavior after 26-week administration of a supplement containing luteolin from chamomile (100 mg), quercetin (70 mg), and the quercetin glycoside rutin (30 mg); 1 capsule per 10 kg of weight was given daily with food. Changes in raw and age-equivalent scores were significant for all domains except communication raw scores and were greater than those expected by maturation per se. No major adverse effects were documented; however, 6 children from the original 50 enrolled withdrew due to increased irritability caused by the formulation.(50)


Animal data

In vitro and animal studies have attempted to elucidate possible mechanisms of action for quercetin in cancer. Aside from its potent scavenging of reactive oxygen and nitrogen species and metal chelation, such mechanisms include antiproliferative, growth-suppressing, and antiangiogenesis activity; inhibition of telomerase and induction of senescence and cell death; and activation of immune and autophagic activity. Studies in rodents have included cancers of the colon, small intestine, tongue, skin, lung, and mammary gland. Other in vivo studies have used melanoma and prostate cancer cells. Quercetin also demonstrates estrogenic activity and may exert a direct effect on androgen receptors in prostate cancer cells.(1, 8, 15, 16, 17, 18, 19, 20, 21)

Clinical data

Clinical trials are lacking to support findings from epidemiological and animal studies. Phase 1 (safety) clinical studies have shown positive results; however, the number of participants was too small to draw conclusions. Other studies have used mixed preparations of quercetin with curcumin or are of limited robustness.(1, 22)

Cardiovascular disease

Animal data

Animal models and studies using isolated cardiovascular tissues suggest a role for quercetin in cardiovascular disease.(1, 15) However, not all effects observed in animal studies have translated to similar effects in humans.(23, 24) Antioxidant effects, including reduced low-density lipoprotein oxidation, decreased experimental reperfusion injury, improved endothelial function, decreased inflammation, and anti-aggregating and antihypertensive effects of quercetin have been demonstrated mostly in rodents.(1, 15, 24) Improved cholesterol profiles and decreased insulin resistance have also been demonstrated,(6, 15) while a role for quercetin metabolites has also been suggested.(25)

Clinical data

Epidemiological studies on the role of flavonoids in decreasing risk factors of cardiovascular morbidity support a place for quercetin.(1, 15) Studies in healthy volunteers and among patients with prehypertension (systolic blood pressure [BP] 120 to 139 mm Hg and diastolic BP 80 to 89 mm Hg) have found no effect of quercetin supplementation on blood pressure.(14, 26) In 23 patients with stage 1 hypertension (systolic BP 140 to 159 mm Hg, diastolic BP 90 to 99 mm Hg), quercetin 730 mg per day over 28 days reduced systolic pressure by 7 mm Hg (±2) and diastolic pressure by 5 mm Hg (±2). Mean arterial pressure was also reduced. Measures of oxidative stress, however, were not affected.(14) In a trial of overweight patients, systolic BP was reduced by 2.6 mm Hg (P < 0.01) in all participants and by 3.7 mm Hg (P < 0.01) in participants with hypertension who consumed quercetin 150 mg per day over 6 weeks.(27) Another clinical trial suggested that the efficacy of quercetin is dependent on the apolipoprotein (Apo) genotype, with subjects presenting with subtype ApoE 3 demonstrating decreased systolic pressure, while those with subtype ApoE 4 did not.(28) Inhibition of platelet aggregation and postulated reductions in the risk of thrombosis have been shown in healthy volunteers given quercetin alone and as onion soup.(29, 30) Limited studies evaluating quercetin’s effect on lipids have produced equivocal results.(28, 31)

Endothelial dysfunction and inflammation biomarkers were evaluated after 35 prehypertensive adults ingested pure epicatechin 100 mg/day and quercetin-3-glucoside 160 mg/day for 4 weeks in a placebo-controlled, double-blind, crossover study. Of the 5 endothelial dysfunction biomarkers measured, soluble endothelial selectin was significantly reduced (P = 0.03) by epicatechin and quercetin supplementation. No other biomarkers were significantly affected by epicatechin; however, pure quercetin supplementation also reduced inflammatory markers (ie, IL-1-beta [P = 0.009], z score for inflammation [P = 0.02]). As a reference, it’s important to note that 4 cups of black tea contain about 19 mg of quercetin.(53)

The effects of quercetin supplementation on CRP (a strong predictor of cardiovascular disease) were assessed in a systematic review and subsequent meta-analysis of 7 double-blind, randomized, placebo-controlled trials (N=549), including 4 crossovers. The studies had sample sizes of 40 to 93 adult participants (1 study enrolled only males, 2 studies enrolled only females) and administered quercetin at dosages of 150 to 500 mg/day for 6 to 10 weeks. Baseline CRP levels ranged from 1.28 to 5.7 mg/L (mean, 3.44 mg/L) in patients with body mass indices of 21.4 to 31.1 kg/m2 and who presented with a variety of conditions (eg, metabolic syndrome, pre-hypertension, mild hypertension, rheumatoid arthritis, type 2 diabetes, various apolipoprotein genotypes). Overall, data showed a statistically significant reduction in CRP (weight mean difference, −0.33 mg/L; P<0.001) in favor of quercetin. The effect size was robust; however, study heterogeneity was significant. Subgroup analysis revealed baseline CRP <3 mg/L, quercetin dose ≥500 mg, duration of treatment ≥8 weeks, mean age of participants ≤45 years, and a parallel study design to be variables that led to significant beneficial results of quercetin on CRP (P<0.001 to P=0.002).(54)


Animal data

Studies in mice have shown efficacy of quercetin supplementation in enhancing physical activity; however, the relevance of data from animal studies is diminished by the availability of clinical trial data and a published meta-analysis.(32, 33)

Clinical data

A meta-analysis, which included 11 clinical trials conducted through July 2010, found that quercetin supplementation marginally improved physical endurance capacity by approximately 3%. Median treatment duration was 11 days, using a median dose of quercetin 1,000 mg per day.(32) Improvement in endurance performance was additionally documented in a meta-analysis of 7 trials identified between 1966 and March, 2011. A significant improvement of 0.74% (P = 0.02) in endurance performance was noted; however, this result was influenced mostly by the positive effect attained in untrained subjects (0.83%) versus trained participants (0.09%). VO2max was also significantly increased (P = 0.02). No heterogeneity was noted among studies.(51)

Iron overload

Clinical data

Limited data from 71 patients with beta-thalassemia major enrolled in a double-blind, randomized, placebo-controlled trial showed that administration of 500 mg/day quercetin with standard chelation therapy significantly reduced serum iron (P=0.036) and ferritin (P=0.043) after 12 weeks compared to placebo. Transferrin, transferrin saturation, and high-sensitivity C-reactive protein were also significantly improved with quercetin administration (P=0.045, P=0.008, P=0.046, respectively).(55)

Nervous system

Studies suggestive of a neuroprotective role have been conducted in human and animal nervous system tissues and in vitro in animals.(36) Clinical studies are lacking, except for a preliminary report on the role of quercetin in peripheral neuropathy due to diabetes, which found improvements in symptoms.(37)


Typical dietary quercetin intake based on fruit and vegetable consumption is estimated to be from 5 to 100 mg per day. Heavy consumption of foods rich in quercetin, such as apples or onions, could lead to daily intakes of up to 500 mg.1, 5, 7, 15 The effective dose is increased when eaten with a fatty meal or in the presence of apple pectin, oligosaccharides, and lecithin.3, 5

Most clinical studies use quercetin 500 to 1,000 mg per day in divided doses.1, 14, 32

As a dietary supplement, 2 weeks of quercetin 50 mg achieved a 178% increase in serum levels, while quercetin 100 mg increased the levels by 359%, and quercetin 500 mg increased serum levels by 570%, although with wide individual variation.38 Based on animal studies, quercetin accumulates in the lungs, liver, kidneys, and small intestine, with lower levels seen in the brain, heart, and spleen. It is eliminated via the renal, fecal, and respiratory systems.7, 9, 15, 39

Pregnancy / Lactation

GRAS when consumed as food. Avoid dosages above those found in foods because information regarding safety and efficacy in pregnancy and lactation is lacking for such doses. Fetal growth retardation was observed in a study in rats exposed to quercetin by oral gavage. No signs of embryonic viability or morphology were apparent.40


Caffeine and caffeine-containing products: Quercetin may increase the serum concentration of caffeine and caffeine-containing products. No action needed.(44, 45)

Chlorzoxazone: CYP2E1 inhibitors (weak) may increase the serum concentration of chlorzoxazone. No action needed.(46, 48, 49)

Cyclosporine (systemic): Quercetin may increase the serum concentration of cyclosporine (systemic). Monitor therapy.(43)

Diclofenac (systemic): Quercetin may increase the serum concentration of diclofenac (systemic). Monitor therapy.(57)

Fexofenadine: Quercetin may increase the serum concentration of fexofenadine. No action needed.(42)

Fosphenytoin-phenytoin: CYP2C9 inhibitors (weak) may increase the serum concentration of fosphenytoin-phenytoin. Monitor therapy.(58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

Midazolam: Quercetin may decrease the serum concentration of midazolam. No action needed.(41, 78, 79, 80)

Pravastatin: Quercetin may increase the serum concentration of pravastatin. No action needed.(81)

Tolbutamide: CYP2C9 inhibitors (weak) may increase the serum concentration of tolbutamide. Monitor therapy.(82, 83, 84, 85, 86)

Vitamin K antagonists: CYP2C9 inhibitors (weak) may increase the serum concentration of vitamin K antagonists. Monitor therapy.(52, 87, 88, 89, 90, 91, 92, 93, 94)

Adverse Reactions

At oral supplemental doses of up to 1,000 mg/day, taken for up to 12 weeks, no evidence of toxicity or clinically important adverse effects have been found; however, data on long-term safety at high doses are lacking.5, 7 Clinical studies report no clinically important adverse effects.14, 27


Quercetin shows in vitro mutagenicity in the Ames test, and reports of mutagenicity in the 1970s led to concerns about its safety.5, 7 Under certain circumstances, quercetin exhibits both radical scavenging and pro-oxidant activity.1, 5 In 1999, however, the International Agency for Research on Cancer classified quercetin as "not classifiable as to its carcinogenicity" to humans.5, 40 Most in vivo studies have shown that quercetin is not carcinogenic and may be protective against genotoxicants.1

Dietary quercetin undergoes first-pass metabolism in the gut and liver and is almost completely metabolized, reducing the potential for toxicity. At oral supplemental doses of up to 1,000 mg per day taken for up to 12 weeks, no evidence of toxicity has been found; however, data on long-term safety at high doses are lacking.5, 7 Nephrotoxicity was reported with the use of high-dose IV quercetin in a patient with compromised health.5, 15



This information relates to an herbal, vitamin, mineral or other dietary supplement. This product has not been reviewed by the FDA to determine whether it is safe or effective and is not subject to the quality standards and safety information collection standards that are applicable to most prescription drugs. This information should not be used to decide whether or not to take this product. This information does not endorse this product as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this product. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from your health care provider. You should talk with your health care provider for complete information about the risks and benefits of using this product.

This product may adversely interact with certain health and medical conditions, other prescription and over-the-counter drugs, foods, or other dietary supplements. This product may be unsafe when used before surgery or other medical procedures. It is important to fully inform your doctor about the herbal, vitamins, mineral or any other supplements you are taking before any kind of surgery or medical procedure. With the exception of certain products that are generally recognized as safe in normal quantities, including use of folic acid and prenatal vitamins during pregnancy, this product has not been sufficiently studied to determine whether it is safe to use during pregnancy or nursing or by persons younger than 2 years of age.

Frequently asked questions

1. Bischoff SC. Quercetin: Potentials in the prevention and therapy of disease. Curr Opin Clin Nutr Metab Care. 2008;11(6):733-740.18827577
2. Nemeth K, Piskula MK. Food content, processing, absorption and metabolism of onion flavonoids. Crit Rev Food Sci Nutr. 2007;47(4):397-409.17457724
3. Lee J, Mitchell AE. Pharmacokinetics of quercetin absorption from apples and onions in healthy humans. J Agric Food Chem. 2012;60(15):3874-3881.22439822
4. Slimestad R, Fossen T, Vågen IM. Onions: a source of unique dietary flavonoids. J Agric Food Chem. 2007;55(25):10067-10080.17997520
5. Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol. 2007;45(11):2179-2205.17698276
6. Perez-Vizcaino F, Duarte J. Flavonols and cardiovascular disease. Mol Aspects Med. 2010;31(6):478-494.20837053
7. Boots AW, Haenen GR, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol. 2008;585(2-3):325-337.18417116
8. Dolatabadi JE. Molecular aspects on the interaction of quercetin and its metal complexes with DNA. Int J Biol Macromol. 2011;48(2):227-233.21115036
9. Moon YJ, Wang L, DiCenzo R, Morris ME. Quercetin pharmacokinetics in humans. Biopharm Drug Dispos. 2008;29(4):205-217.18241083
10. Pandey AK, Patnaik R, Muresanu DF, Sharma A, Sharma HS. Quercetin in hypoxia-induced oxidative stress: novel target for neuroprotection. Int Rev Neurobiol. 2012;102:107-146.22748828
11. Vitaglione P, Morisco F, Caporaso N, Fogliano V. Dietary antioxidant compounds and liver health. Crit Rev Food Sci Nutr. 2004;44(7-8):575-586.15969329
12. Stefek M, Karasu C. Eye lens in aging and diabetes: effect of quercetin. Rejuvenation Res. 2011;14(5):525-534.21978083
13. Boots AW, Drent M, de Boer VC, Bast A, Haenen GR. Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis. Clin Nutr. 2011;30(4):506-512.21324570
14. Edwards RL, Lyon T, Litwin SE, Rabovsky A, Symons JD, Jalili T. Quercetin reduces blood pressure in hypertensive subjects. J Nutr. 2007;137(11):2405-2411.17951477
15. Russo M, Spagnuolo C, Tedesco I, Bilotto S, Russo GL. The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem Pharmacol. 2012;83(1):6-15.21856292
16. Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett. 2008;269(2):315-325.18467024
17. Lee KW, Lee HJ. The roles of polyphenols in cancer chemoprevention. Biofactors. 2006;26(2):105-121.16823097
18. Mendoza EE, Burd R. Quercetin as a systemic chemopreventative agent: structural and functional mechanisms. Mini Rev Med Chem. 2011;11(14):1216-1221.22070678
19. Vargas AJ, Burd R. Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management. Nutr Rev. 2010;68(7):418-428.20591109
20. Araújo JR, Goncalves P, Martel F. Chemopreventive effect of dietary polyphenols in colorectal cancer cell lines. Nutr Res. 2011;31(2):77-87.21419311
21. Vargas AJ, Sittadjody S, Thangasamy T, Mendoza EE, Limesand KH, Burd R. Exploiting tyrosinase expression and activity in melanocytic tumors: quercetin and the central role of p53. Integr Cancer Ther. 2011;10(4):328-340.21196432
22. Cimino S, Sortino G, Favilla V, et al. Polyphenols: key issues involved in chemoprevention of prostate cancer [published online May 28, 2012]. Oxid Med Cell Longev. 2012;2012:632959.22690272
23. Boesch-Saadatmandi C, Egert S, Schrader C, et al. Effect of quercetin on paraoxonase 1 activity–studies in cultured cells, mice and humans. J Physiol Pharmacol. 2010;61(1):99-105.20228421
24. Perez-Vizcaino F, Duarte J, Jimenez R, Santos-Buelga C, Osuna A. Antihypertensive effects of the flavonoid quercetin. Pharmacol Rep. 2009;61(1):67-75.19307694
25. Ishizawa K, Yoshizumi M, Kawai Y, et al. Pharmacology in health food: metabolism of quercetin in vivo and its protective effect against arteriosclerosis. J Pharmacol Sci. 2011;115(4):466-470.21436601
26. Larson A, Witman MA, Guo Y, et al. Acute, quercetin-induced reductions in blood pressure in hypertensive individuals are not secondary to lower plasma angiotensin-converting enzyme activity or endothelin-1: nitric oxide. Nutr Res. 2012;32(8):557-564.22935338
27. Egert S, Bosy-Westphal A, Seiberl J, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: A double-blinded, placebo-controlled cross-over study. Br J Nutr. 2009;102(7):1065-1074.19402938
28. Egert S, Boesch-Saadatmandi C, Wolffram S, Rimbach G, Muller MJ. Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. J Nutr. 2010;140(2):278-284.20032478
29. Hubbard GP, Wolffram S, Lovegrove JA, Gibbins JM. Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. J Thromb Haemost. 2004;2(12):2138-2145.15613018
30. Hubbard GP, Wolffram S, de Vos R, et al. Ingestion of onion soup high in quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in man: a pilot study. Br J Nutr. 2006;96(3):482-488.16925853
31. Talirevic E, Jelena S. Quercetin in the treatment of dyslipidemia. Med Arh. 2012;66(2):87-88.22486135
32. Kressler J, Millard-Stafford M, Warren GL. Quercetin and endurance exercise capacity: A systematic review and meta-analysis. Med Sci Sports Exerc. 2011;43(12):2396-2404.21606866
33. Nieman DC, Laupheimer MW, Ranchordas MK, Burke LM, Stear SJ, Castell LM. A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance–part 33. Br J Sports Med. 2012;46(8):618-620.22685173
34. Heinz SA, Henson DA, Nieman DC, Austin MD, Jin F. A 12-week supplementation with quercetin does not affect natural killer cell activity, granulocyte oxidative burst activity or granulocyte phagocytosis in female human subjects. Br J Nutr. 2010;104(6):849-857.20500927
35. Heinz SA, Henson DA, Austin MD, Jin F, Nieman DC. Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial. Pharmacol Res. 2010;62(3):237-242.20478383
36. Ossola B, Kääriäinen TM, Mannisto PT. The multiple faces of quercetin in neuroprotection. Expert Opin Drug Saf. 2009;8(4):397-409.19538101
37. Valensi P, Le Devehat C, Richard JL, et al. A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005;19(5):247-253.16112498
38. Jin F, Nieman DC, Shanely RA, Knab AM, Austin MD, Sha W. The variable plasma quercetin response to 12-week quercetin supplementation in humans. Eur J Clin Nutr. 2010;64(7):692-697.20517329
39. Bieger J, Cermak R, Blank R, et al. Tissue distribution of quercetin in pigs after long-term dietary supplementation. J Nutr. 2008;138(8):1417-1420.18641184
40. Quercetin. IARC Monogr Eval Carcinog Risks Hum. 1999;73:497-515.
41. Duan KM, Wang SY, Ouyang W, Mao YM, Yang LJ. Effect of quercetin on CYP3A activity in Chinese healthy participants. J Clin Pharmacol. 2012;52(6):940-946.21680781
42. Kim KA, Park PW, Park JY. Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. Eur J Clin Pharmacol. 2009;65(6):609-614.19221726
43. Choi JS, Choi BC, Choi KE. Effect of quercetin on the pharmacokinetics of oral cyclosporine. Am J Health Syst Pharm. 2004;61(22):2406-2409.15581264
44. Chen Y, Xiao P, Ou-Yang DS, et al. Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers. Clin Exp Pharmacol Physiol. 2009;36(8):828-833.19215233
45. Xiao J, Huang WH, Peng JB, et al. Quercetin significantly inhibits the metabolism of caffeine, a substrate of cytochrome P450 1A2 unrelated to CYP1A2*1C (-2964G > A) and *1F (734C > A) gene polymorphisms. Biomed Res Int. 2014:405071.25025048
46. Bedada SK, Neerati P. Resveratrol pretreatment affects CYP2E1 activity of chlorzoxazone in healthy human volunteers. Phytother Res. 2016;30(3):463-468.26680654
47. Kim KA, Park PW, Kim HK, Ha JM, Park JY. Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects. J Clin Pharmacol. 2005;45(8):941-946.16027405
48. Bedada SK, Neerati P. The effect of quercetin on the pharmacokinetics of chlorzoxazone, a CYP2E1 substrate, in healthy subjects. Eur J Clin Pharmacol. 2018;74(1):91-97.28983678
49. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005;77(5):415-426.15900287
50. Taliou A, Zintzaras E, Lykouras L, Francis K. An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clin Ther. 2013;35(5):592-602.23688534
51. Pelletier DM, Lacerte G, Goulet ED. Effects of quercetin supplementation on endurance performance and maximal oxygen consumption: a meta-analysis. Int J Sport Nutr Exerc Metab. 2013(1);23:73-82.22805526
52. Woodward CJ, Deyo ZM, Donahue KE, Deal AM, Hawes EM. Clinically relevant interaction between warfarin and scuppernongs, a quercetin containing muscadine grape: continued questions surrounding flavonoid-induced warfarin interactions. BMJ Case Rep. 2014;2014:Pii: bcr2013009608.24966255
53. Dower JI, Geleijnse JM, Gijsbers L, Schalkwijk C, Kromhout D, Hollman PC. Supplementation of the pure flavonoids epicatechin and quercetin affects some biomarkers of endothelial dysfunction and inflammation in (pre)hypertensive adults: a randomized, double-blind, placebo-controlled, crossover trial. J Nutr. 2015;145(7):1459-1463.25972527
54. Mohammadi-Sartang M, Mazloom Z, Sherafatmanesh S, Ghorbani M, Firoozi D. Effects of supplementation with quercetin on plasma c-reactive protein concentrations: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Nutr. 2017;71(9):1033-1039.28537580
55. Sajadi Hezaveh Z, Azarkeivan A, Janani L, Hosseini S, Shidfar F. The effect of quercetin on overload and inflammation in β-thalassemia major patients: a double-blind randomized clinical trial. Complement Ther Med. 2019;46:24-28.31519283
56. Dehghani F, Sezavar Seyedi Jandaghi SH, Janani L, Sarebanhassanabadi M, Emamat H, Vafa M. Effects of quercetin supplementation on inflammatory factors and quality of life in post-myocardial infarction patients: A double blind, placebo-controlled, randomized clinical trial. Phytother Res. 2021;35(4):2085-2098.33216421
57. Bedada SK, Neerati P. Evaluation of the effect of quercetin treatment on CYP2C9 enzyme activity of diclofenac in healthy human volunteers. Phytother Res. 2018;32(2):305-311.29168292
58. Ahmad S. Amiodarone and phenytoin: interaction. J Am Geriatr Soc. 1995;43(12):1449-1450.7490410
59. Ballek RE, Reidenberg MM, Orr L. Inhibition of diphenylhydantoin metabolism by chloramphenicol. Lancet. 1973;1(7795):150.4118490
60. Blyden GT, Scavone JM, Greenblatt DJ. Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam. J Clin Pharmacol. 1988;28(3):240-245.3360972
61. Brickell K, Porter D, Thompson P. Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports. Br J Cancer. 2003;89(4):615-616.12915866
62. Christensen LK, Skovsted L. Inhibition of drug metabolism by chloramphenicol. Lancet. 1969;2(7635):1397-1399.4188280
63. Dilantin (phenytoin) [prescribing information]. New York, NY: Pfizer Inc; October 2018.
64. Gilbar PJ, Brodribb TR. Phenytoin and fluorouracil interaction. Ann Pharmacother. 2001;35(11):1367-1370.11724084
65. Jensen JC, Gugler R. Interaction between metronidazole and drugs eliminated by oxidative metabolism. Clin Pharmacol Ther. 1985;37(4):407-410.3979002
66. Konishi H, Morita K, Minouchi T, Nakajima M, Matsuda M, Yamaji A. Probable metabolic interaction of doxifluridine with phenytoin. Ann Pharmacother. 2002;36(5):831-834.11978162
67. Koup JR, Gibaldi M, McNamara P, Hilligoss DM, Colburn WA, Bruck E. Interaction of chloramphenicol with phenytoin and phenobarbital. Case report. Clin Pharmacol Ther. 1978;24(5):571-575.699481
68. McGovern B, Geer VR, LaRaia PJ, Garan H, Ruskin JN. Possible interaction between amiodarone and phenytoin. Ann Intern Med. 1984;101(5):650-651.6486598
69. Nolan PE, Marcus FI, Hoyer GL, Bliss M, Gear K. Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers. Clin Pharmacol Ther. 1989;46(1):43-50.2743707
70. Nolan PE, Erstad BL, Hoyer GL, Bliss M, Gear K, Marcus FI. Steady-state interaction between amiodarone and phenytoin in normal subjects. Am J Cardiol. 1990;65(18):1252-1257.2337037
71. Ogutu BR, Newton CR, Muchohi SN, Otieno GO, Kokwaro GO. Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration. Br J Clin Pharmacol. 2002;54(6):635-642.12492612
72. Rose JQ, Choi HK, Schentag JJ, Kinkel WR, Jusko WJ. Intoxication caused by interaction of chloramphenicol and phenytoin. JAMA. 1977;237(24):2630-2631.576989
73. Rosemergy I, Findlay M. Phenytoin toxicity as a result of 5-fluorouracil administration. N Z Med J. 2002;115(1159):U124.12362168
74. Shackleford EJ, Watson FT. Amiodarone-phenytoin interaction. Drug Intell Clin Pharm. 1987;21(11):921.3678068
75. Tsuda A, Fujiyama J, Miki A, Hori S, Ohtani H, Sawada Y. The first case of phenytoin intoxication associated with the concomitant use of phenytoin and TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium. Cancer Chemother Pharmacol. 2008;62(3):427-432.18026730
76. Vincent FM, Mills L, Sullivan JK. Chloramphenicol-induced phenytoin intoxication. Ann Neurol. 1978;3(5):469.727733
77. Wakisaka S, Shimauchi M, Kaji Y, Nonaka A, Kinoshita K. Acute phenytoin intoxication associated with the antineoplastic agent UFT. Fukuoka Igaku Zasshi. 1990;81(4):192-196.2116374
78. Mohos V, Fliszar-Nyul E, Ungvari O, et al. Inhibitory effects of quercetin and its main methyl, sulfate, and glucuronic acid conjugates on cytochrome P450 enzymes, and on OATP, BCRP and MRP2 transporters. Nutrients. 2020;12(8):2306.32751996
79. Nguyen MA, Staubach P, Wolffram S, Langguth P. The influence of single-dose and short-term administration of quercetin on the pharmacokinetics of midazolam in humans. J Pharm Sci. 2015;104(9):3199-3207.25988261
80. Yim SK, Kim K, Chun SH, et al. Screening of human CYP1A2 and CYP3A4 inhibitors from seaweed in silico and in vitro. Mar Drugs. 2020;18(12):603.33260381
81. Wu LX, Guo CX, Chen WQ, et al. Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment. Br J Clin Pharmacol. 2012;73(5):750-757.22114872
82. Brunova E, Slabochova Z, Platilova H, Pavlik F, Grafnetterova J, Dvoracek K. Interaction of tolbutamide and chloramphenicol in diabetic patients. Int J Clin Pharmacol Biopharm. 1977;15(1):7-12.838527
83. Madsen H, Enggaard TP, Hansen LL, Klitgaard NA, Brosen K. Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. Clin Pharmacol Ther. 2001;69(1):41-47.11180037
84. Miners JO, Foenander T, Wanwimolruk S, Gallus AS, Birkett DJ. The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination. Eur J Clin Pharmacol. 1982;22(4):321-326.7106168
85. Orladeyo (berotralstat) [prescribing information]. Durham, NC: BioCryst Pharmaceuticals Inc; December 2020.
86. Wing LM, Miners JO. Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition.Br J Clin Pharmacol. 1985;20(5):482-485.3878154
87. Accolate (zafirlukast) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; November 2013.
88. Hurtado FK, de Braud F, De Vastro Carpeno J, et al. Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK positive advanced tumors. Cancer Chemother Pharmacol. 2021;87(4):475-486.33394101
89. Lash DB, Ward S. CYP2C9-mediated warfarin and milk thistle interaction. J Clin Pharm Ther. 2020;45(2):368-369.31633199
90. Leone R, Ghiotto E, Conforti A, Velo G. Potential interaction between warfarin and ocular chloramphenicol. Ann Pharmacother. 1999;33(1):114.9972397
91. Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol. 2003;56(supp 1):24-29.14616410
92. Takahashi H, Sato T, Shimoyama Y, et al. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. Clin Pharmacol Ther. 1999;66(6):569-581.10613612
93. Xiao JJ, Nowak D, Ramlau R, et al. Evaluation of drug-drug interactions of rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp substrates in patients with an advanced solid tumor. Clin Transl Sci. 2019;12(1):58-65.30427584
94. Yamamoto H, Habu Y, Yano I, et al. Comparison of the effects of azole antifungal agents on the anticoagulant activity of warfarin. Biol Pharm Bull. 2014;37(12):1990-1993.25451849
95. Yao J, Zhao J, Wen JR, et al. Flavonoid-containing supplements for preventing acute respiratory tract infections: A systematic review and meta-analysis of 20 randomized controlled trials. Complement Ther Med. 2022;70:102865. doi:10.1016/j.ctim.2022.10286535940344

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.